Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin ImmunoconjugatePresented in part at the 1997 Annual Meeting of the American Society of Clinical Oncology, Denver, CO; the 1997 European Cancer Conference, Hamburg, Germany; and the 1997 Annual Meeting of the American Society of Hematology, San Diego, CA.

摘要: Abstract Leukemic blast cells express the CD33 antigen in most patients with acute myeloid leukemia (AML), but this is not expressed by hematopoietic stem cells. We conducted a study to determine whether normal hematopoiesis could be restored AML selective ablation of expressing antigen. In dose escalation study, 40 relapsed or refractory CD33+ were treated an immunoconjugate (CMA-676) consisting humanized anti-CD33 antibody linked potent antitumor antibiotic calicheamicin. The capacity leukemic efflux 3,3'-diethyloxacarbocyanine iodide (DiOC2) was used estimate pretreatment functional drug resistance. Leukemia eliminated from blood and marrow 8 (20%) patients; counts returned three (8%) patients. A high rate clinical response observed leukemias characterized low dye vitro. Infusions CMA-676 generally well tolerated, postinfusion syndrome fever chills common toxic effect. Two who at highest level (9 mg/m2) neutropenic >5 weeks after last CMA-676. These results show that targeted can selectively ablate malignant some AML.